This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Most customers, rivals offer no objection to Merck-Sigma merger deal

By Carolina Guerra ( June 8, 2015, 22:19 GMT | Insight) -- Most customers and rivals consulted by the Brazilian antitrust authority offered no objections to the planned $17 billion acquisition by German pharmaceutical company Merck KGaA of rival Sigma-Aldrich. About 100 companies provided opinions to the regulator, with about 15 publicly raising some kind of concern, such as the potential for high concentration in some markets and the possibility that some product offerings could be reduced.Most customers and rivals consulted by the Brazilian antitrust authority offered no objections to German pharmaceutical company Merck KGaA's planned $17 billion acquisition of rival Sigma-Aldrich....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login